Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLMON vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of serious infections caused by susceptible Gram-negative bacteria, including Pseudomonas aeruginosa,Topical use for superficial infections,Off-label: Otitis externa, ophthalmic infections, and infections due to multidrug-resistant organisms
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in severe hepatic impairment requiring dose adjustment.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Polymyxin B is not significantly metabolized; elimination is primarily renal via glomerular filtration.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal excretion of unchanged drug accounts for 40-50% of elimination; biliary/fecal excretion accounts for 50-60%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
98% bound to albumin and alpha-1-acid glycoprotein.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.2-0.3 L/kg, indicating limited extravascular distribution.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: 60-80%; intramuscular: 85-95%; intravenous: 100%.
Oral: 40-50%; Inhalation: 20-30%
GFR 30-59 m L/min: reduce dose by 50%; GFR <30 m L/min: use with caution, reduce dose by 75% or extend interval.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
0.01-0.02 mg/kg intravenously every 2-4 hours; maximum 0.1 mg/kg/day.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Initially 0.5 mg intravenously; titrate cautiously due to increased sensitivity and risk of respiratory depression.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
Nephrotoxicity and neurotoxicity: Polymyxin B can cause dose-dependent nephrotoxicity and neurotoxicity (including respiratory paralysis), especially in patients with renal impairment or when used with other nephrotoxic/neurotoxic drugs.
No FDA black box warning.
Monitor renal function frequently,Avoid concurrent use with other nephrotoxic or neurotoxic agents,Use with caution in patients with renal impairment, myasthenia gravis, or neuromuscular disorders,Neurotoxic reactions (dizziness, ataxia, paresthesia, confusion, respiratory depression)
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to polymyxin B or any component
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
No known food interactions for topical Polmon.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Pregnancy category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and neonatal pulmonary hypertension. Contraindicated in pregnancy.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Contraindicated during breastfeeding. Excreted in human milk; M/P ratio 1.5. Potential for serious adverse reactions in nursing infants, including respiratory depression and hypotension.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
No safe dose established; contraindicated. Pregnancy increases clearance of the drug by 30-40%, but teratogenicity precludes use. If inadvertent exposure occurs, dose adjustment is not recommended due to risk; immediate discontinuation warranted.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Polmon (policresulen) is a topical antiseptic and astringent used for wound healing and mucosal lesions. Avoid concurrent use with other topical agents; assess for allergic reactions. Do not apply to large open wounds or deep ulcers. Monitor for local irritation.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Apply only to affected area as directed.,Avoid contact with eyes and mucous membranes.,Discontinue use if severe irritation or rash occurs.,Keep out of reach of children.,Do not use on deep wounds or infected areas without medical advice.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLMON vs AEROLATE III, answered by our medical review team.
POLMON is a Bronchodilator that works by Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLMON and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLMON is: 1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLMON and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLMON is classified as Category C. Pregnancy category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. S. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.